Genetic basis of acute myeloid leukemia (AML): The most common molecular changes in patients with normal karyotype

[1] Fallini B, Brunetti L, Sportoletti P, Martelli M. NPM1-mutated acute myeloid leukemia: From bench to bedside. Blood. 2020; 136: 1707–1721. FalliniB BrunettiL SportolettiP MartelliM NPM1-mutated acute myeloid leukemia: From bench to bedside Blood 2020 136 1707 1721 10.1182/blood.201900422632609823 Search in Google Scholar

[2] Metzeler K, Herold T, Rothenberg-Turley M, Amler S, Sauerland M, Gorlich D, Schneider S, Konstandin N, Dufour A, Braundl K, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016; 128: 686–698. MetzelerK HeroldT Rothenberg-TurleyM AmlerS SauerlandM GorlichD SchneiderS KonstandinN DufourA BraundlK Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia Blood 2016 128 686 698 10.1182/blood-2016-01-69387927288520 Search in Google Scholar

[3] Hassan N, Said F, Shafik R, Abdellateif M. Dysregulation of CCAAT/enhancer binding protein-alpha (CEBPA) expression in the bone marrow of acute myeloid leukemia patients. Egypt J Med. Hum Genet. 2021; 22. HassanN SaidF ShafikR AbdellateifM Dysregulation of CCAAT/enhancer binding protein-alpha (CEBPA) expression in the bone marrow of acute myeloid leukemia patients Egypt J Med. Hum Genet 2021 22 10.1186/s43042-021-00154-z Search in Google Scholar

[4] Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99: 4326–4335. ThiedeC SteudelC MohrB SchaichM SchakelU PlatzbeckerU WermkeM BornhauserM RitterM NeubauerA Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis Blood 2002 99 4326 4335 10.1182/blood.V99.12.4326 Search in Google Scholar

[5] Gilliland G, Griffin J. The role of FLT3 in hematopoiesis and leukemia. Blood. 2002;100: 1532–1542. GillilandG GriffinJ The role of FLT3 in hematopoiesis and leukemia Blood 2002 100 1532 1542 10.1182/blood-2002-02-049212176867 Search in Google Scholar

[6] Papaemmanuil E, Grstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, Potter N, Heuser M, Thol F, Bolli N, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374: 2209–2221. PapaemmanuilE GrstungM BullingerL GaidzikV PaschkaP RobertsN PotterN HeuserM TholF BolliN Genomic classification and prognosis in acute myeloid leukemia N Engl J Med 2016 374 2209 2221 10.1056/NEJMoa1516192497999527276561 Search in Google Scholar

[7] Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T, Dombret H, Ebert B, Fenaux P, Larson R, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129: 424–447. DöhnerH EsteyE GrimwadeD AmadoriS AppelbaumF BuchnerT DombretH EbertB FenauxP LarsonR Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Blood 2017 129 424 447 10.1182/blood-2016-08-733196529196527895058 Search in Google Scholar

[8] The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368: 2059–2074. The Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N Engl J Med 2013 368 2059 2074 10.1056/NEJMoa1301689376704123634996 Search in Google Scholar

[9] Herold T, Rothenberg-Thurley M, Grunwald V, Janke H, Goerlich D, Sauerland M, Konstandin N, Dufour A, Schneider S, Neusser M, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020; 34: 3161–3172. HeroldT Rothenberg-ThurleyM GrunwaldV JankeH GoerlichD SauerlandM KonstandinN DufourA SchneiderS NeusserM Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia Leukemia 2020 34 3161 3172 10.1038/s41375-020-0806-0768597532231256 Search in Google Scholar

[10] Dalenc F, Drouet J, Ader I, Delmas C, Rochaix P, Favre G, Cohen-Jonathen E, Toulas C. Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells. Int J Cancer. 2002; 100: 662–668. DalencF DrouetJ AderI DelmasC RochaixP FavreG Cohen-JonathenE ToulasC Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells Int J Cancer 2002 100 662 668 10.1002/ijc.1055812209603 Search in Google Scholar

[11] Ahn J, Liu X, Cheng D, Peng J, Chan P, Wade P, Ye K. Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD. Mol Cell. 2005; 18: 435–445. AhnJ LiuX ChengD PengJ ChanP WadeP YeK Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD Mol Cell 2005 18 435 445 10.1016/j.molcel.2005.04.01015893727 Search in Google Scholar

[12] Eirin-Lopez JM, Frehlick L, Ausio J. Long-term evolution and functional diversification in the members of the nucleophosmin/nucleoplasmin family of nuclear chaperones. Genetics. 2006; 173: 1835–1850. Eirin-LopezJM FrehlickL AusioJ Long-term evolution and functional diversification in the members of the nucleophosmin/nucleoplasmin family of nuclear chaperones Genetics 2006 173 1835 1850 10.1534/genetics.106.058990156971216751661 Search in Google Scholar

[13] Lee S, Park J, Kim S, Park E, Yun Y, Kwon J. A proteomics approach for the identification of nucleophosmin and heterogenous nuclear ribonucleoprotein C1/C2 as chromatin-biding proteins in response to DNA double-strand breaks. Biochem J. 2005; 388: 7–15. LeeS ParkJ KimS ParkE YunY KwonJ A proteomics approach for the identification of nucleophosmin and heterogenous nuclear ribonucleoprotein C1/C2 as chromatin-biding proteins in response to DNA double-strand breaks Biochem J 2005 388 7 15 10.1042/BJ20042033118668815737070 Search in Google Scholar

[14] Zatsepina O, Rousselet A, Chan P, Olson M, Jordan E, Bornens M. The nucleolar phosphoprotein B23 redistributes in part to the spindle poles during mitosis. J Cell Sci. 1999; 112: 455–466. ZatsepinaO RousseletA ChanP OlsonM JordanE BornensM The nucleolar phosphoprotein B23 redistributes in part to the spindle poles during mitosis J Cell Sci 1999 112 455 466 10.1242/jcs.112.4.4559914158 Search in Google Scholar

[15] Fallini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006, 107, 4514–4523. FalliniB BolliN ShanJ MartelliMP LisoA PucciariniA BigernaB PasqualucciL MannucciR RosatiR Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML Blood 2006 107 4514 4523 10.1182/blood-2005-11-474516455950 Search in Google Scholar

[16] Fallini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with normal karyotype. N Engl J Med. 2005; 352: 254–266. FalliniB MecucciC TiacciE AlcalayM RosatiR PasqualucciL La StarzaR DiverioD ColomboE SantucciA Cytoplasmic nucleophosmin in acute myelogenous leukemia with normal karyotype N Engl J Med 2005 352 254 266 10.1056/NEJMoa04197415659725 Search in Google Scholar

[17] Rau R, Rodriguez B, Luo M, Jeong M, Rosen A, Rogers J, Campbell C, Daigle S, Deng L, Song Y, et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016; 128: 971–981. RauR RodriguezB LuoM JeongM RosenA RogersJ CampbellC DaigleS DengL SongY DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia Blood 2016 128 971 981 10.1182/blood-2015-11-684225499085627335278 Search in Google Scholar

[18] Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rucker F, Lux S, Blatte T, Skambraks S, Kronke J, Heidel F, Schnoder T, et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun. 2019: 10:2031. CocciardiS DolnikA Kapp-SchwoererS RuckerF LuxS BlatteT SkambraksS KronkeJ HeidelF SchnoderT Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation Nat Commun 2019 10 2031 10.1038/s41467-019-09745-2649771231048683 Search in Google Scholar

[19] Lagunas-Rangel F, Chavez-Valencia V, Gomez-Guijosa M, Cortes-Penagos C. Acute myeloid leukemia - genetic alterations and their clinical prognosis. IJHOSCR. 2017; 4: 328–339. Lagunas-RangelF Chavez-ValenciaV Gomez-GuijosaM Cortes-PenagosC Acute myeloid leukemia - genetic alterations and their clinical prognosis IJHOSCR 2017 4 328 339 Search in Google Scholar

[20] Gorello P, Cazzaniga G, Alberti F, Dell’Oro M, Gottardi E, Specchia G, Roti G, Rosati R, Martelli M, Diverio D, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006; 20: 1103–1108. GorelloP CazzanigaG AlbertiF Dell’OroM GottardiE SpecchiaG RotiG RosatiR MartelliM DiverioD Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations Leukemia 2006 20 1103 1108 10.1038/sj.leu.240414916541144 Search in Google Scholar

[21] Libura M, Pawełczyk M, Florek I, Matiakowska K, Jaźwiec B, Borg K, Solarska I, Zawada M, Czekalska S, Libura J, et al. CEBPA copy number variations in normal karyotype acute myeloid leukemia: possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis. Blood Cells Mol Dis. 2015; 55: 284–292. LiburaM PawełczykM FlorekI MatiakowskaK JaźwiecB BorgK SolarskaI ZawadaM CzekalskaS LiburaJ CEBPA copy number variations in normal karyotype acute myeloid leukemia: possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis Blood Cells Mol Dis 2015 55 284 292 10.1016/j.bcmd.2015.07.00226460249 Search in Google Scholar

[22] Nakao M, Yokota S, Iwai T, Kaneko H, Kashima K, Sonoda Y, Fujimoto T, Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996; 10: 1911–1918. NakaoM YokotaS IwaiT KanekoH KashimaK SonodaY FujimotoT MisawaS Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 1996 10 1911 1918 Search in Google Scholar

[23] Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, Small D, Rassool F. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: Implications for poor prognosis in AML. Blood. 2008; 111: 3173–3182. SallmyrA FanJ DattaK KimKT GrosuD ShapiroP SmallD RassoolF Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: Implications for poor prognosis in AML Blood 2008 111 3173 3182 10.1182/blood-2007-05-09251018192505 Search in Google Scholar

[24] Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T. Diversity of the juxtamembrane and TKD1 mutations (exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer. 2012; 51: 910–924. SchnittgerS BacherU HaferlachC AlpermannT KernW HaferlachT Diversity of the juxtamembrane and TKD1 mutations (exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data Genes Chromosomes Cancer 2012 51 910 924 10.1002/gcc.2197522674490 Search in Google Scholar

[25] Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021; 11: 104. DaverN VenugopalS RavandiF FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm Blood Cancer J 2021 11 104 10.1038/s41408-021-00495-3815992434045454 Search in Google Scholar

[26] Pabst T, Mueller B, Zhang P, Radomska H, Narravyla S, Schnittger S, Behre G, Hiddemann W, Tenen W. Dominant-negative mutations of CEBPA, encoding CCAAt/enhancer biding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet. 2001; 27: 263–270. PabstT MuellerB ZhangP RadomskaH NarravylaS SchnittgerS BehreG HiddemannW TenenW Dominant-negative mutations of CEBPA, encoding CCAAt/enhancer biding protein-α (C/EBPα), in acute myeloid leukemia Nat Genet 2001 27 263 270 10.1038/8582011242107 Search in Google Scholar

[27] Su L, Shi YY, Liu ZY, Gao SJ. Acute myeloid leukemia with CEBPA muttions: Current progress and future directions. Front Oncol. 2022; 12: 806137. SuL ShiYY LiuZY GaoSJ Acute myeloid leukemia with CEBPA muttions: Current progress and future directions Front Oncol 2022 12 806137 10.3389/fonc.2022.806137884402035178345 Search in Google Scholar

[28] Ley T, Ding L, Walter M, McLellan M, Lamprecht T, Larson D, Kandoth C, Payton J, Baty J, Welch J, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363: 2424–2433. LeyT DingL WalterM McLellanM LamprechtT LarsonD KandothC PaytonJ BatyJ WelchJ DNMT3A mutations in acute myeloid leukemia N Engl J Med 2010 363 2424 2433 10.1182/blood.V118.21.SCI-31.SCI-31 Search in Google Scholar

[29] Godfrey L, Crump N, Thorne R, Lau IJ, Repapi E, Dimou D, Smith A, Harman J, Telenius J, Oudelaar A, et al. DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation. Nat Commun. 2019; 10: 2803. GodfreyL CrumpN ThorneR LauIJ RepapiE DimouD SmithA HarmanJ TeleniusJ OudelaarA DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation Nat Commun 2019 10 2803 10.1038/s41467-019-10844-3659495631243293 Search in Google Scholar